This is a big deal. CALPERS is removing themselves from the cesspool that is the hedge fund world, which represents about $4 billion. What’s worse is that this could become a trend for pensions around the country, which in turn may lead to forced liquidations–further jarring markets. But even if stocks soften a bit here, there are plenty of go-to names to devour on the cheap.
Look towards GILD (I am long), trading 11x eps, on pace to generate over $15 billion in free cash flow next year. This is a company that may begin to aggressively buy back its own shares or increase its dividend. By the way, they cured hep c.
Two biotechs worth buying on dips are ACHN and ARWR. ACHN has a cheaper hep c drug than GILD’s and the data has been impressive. ARWR (I am long) is working on a hep b cure and is a possible buyout candidate. Other biotechs that I will buy on dips include JAZZ (I am long), XON, GEVA, ALNY and SGEN (I am long).
Let’s not forget about the oil boom in the Bakken and Permian Basin. I like fracking sand companies SLCA (I am long), EMES and HCLP. And exploration companies FANG, OAS and CLR.
Lastly, there is the tech arm to this market. Web 2.0 is the only way to play it. However, valuations are stretched and if we get a decent pullback, you might lose your scalps with these names. Nevertheless, YELP (I am long), AAPL (I am long), TRIP and TWTR are must owns–long term. Other high tech names that peak my interest are MBLY, GPRO, PANW (I am long), QIHU, YY and N (I am long).
As an aside, if Shake Shack ever comes public, I will make it my largest position and probably never sell it.
Until then, my trading positions are heavily biased towards utilities and treasuries. I am also excited about my IFON position catching a second wind.
Comments »

